Thermo Fisher Scientific (TMO) beat expectations in Q2 FY2026 on revenue of $12.0B versus the $11.7B estimate (+10.5% YoY) and EPS of $6.03. The next Thermo Fisher Scientific (TMO) earnings date is Oct 28, 2026. Below is the full Thermo Fisher Scientific earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.
$12.0B (vs $11.7B est · +2.5% surprise · +10.5% YoY)
EPS
$6.03 (vs $5.72 est · +5.4% surprise · +9.3% YoY)
Share price
$628.74 (-0.1%)
Market cap
$233.7B
Thermo Fisher Scientific (TMO) Earnings Analysis — beat / miss history
Quarter
Revenue
EPS
EPS surprise
Next-day move
Verdict
Q3 FY2026
$12.0B vs $11.7B est
$6.03 vs $5.72 est
+5.4%
+7.9%
Beat
Q2 FY2026
$11.0B vs $10.9B est
$5.44 vs $5.25 est
+3.6%
-8.6%
Mixed
Q1 FY2026
$12.2B vs $11.9B est
$6.57 vs $6.45 est
+1.9%
-4.8%
Mixed
Q4 FY2025
$11.1B vs $10.9B est
$5.79 vs $5.50 est
+5.3%
+2.5%
Mixed
Q3 FY2025
$10.9B vs $10.7B est
$5.36 vs $5.23 est
+2.5%
+11.1%
Mixed
Q2 FY2025
$10.4B vs $10.2B est
$5.15 vs $5.10 est
+1.0%
-1.9%
In line
Q1 FY2025
$11.4B vs $11.3B est
$6.10 vs $5.94 est
+2.7%
+5.2%
Mixed
Q4 FY2024
$10.6B vs $10.6B est
$5.28 vs $5.25 est
+0.6%
-4.9%
In line
Top institutional holders
Holder
% outstanding
Shares
Value
QoQ change
Blackrock, INC.
8.3%
30.9M
$15.5B
+1.6%
Vanguard Capital Management LLC
6.5%
24.3M
$12.2B
-0.0%
State Street Corp
4.5%
16.8M
$8.4B
+0.6%
Ci Private Wealth, LLC
4.4%
16.2M
$382.5M
+1845.4%
Fmr LLC
3.8%
14.1M
$7.1B
+30.7%
Morgan Stanley
2.9%
10.8M
$5.4B
-0.9%
Jpmorgan Chase & CO
2.3%
8.5M
$4.3B
+25.1%
Geode Capital Management, LLC
2.3%
8.4M
$4.2B
-0.3%
Franklin Resources INC
2.0%
7.3M
$3.6B
+6.7%
Vanguard Portfolio Management LLC
1.7%
6.2M
$3.1B
+1.0%
Recent insider transactions
Insider
Role
Date
Type
Shares
Value
Meyer James
officer: Sr. Vice President & CFO
2026-08-22
Sell
31
$19473
CASPER MARC N
director, officer: Chairman & CEO
2026-08-21
Buy
10K
$3.1M
CASPER MARC N
director, officer: Chairman & CEO
2026-08-20
Sell
909
$568534
CASPER MARC N
director, officer: Chairman & CEO
2026-08-20
Sell
821
$514627
CASPER MARC N
director, officer: Chairman & CEO
2026-08-21
Sell
3K
$1.7M
CASPER MARC N
director, officer: Chairman & CEO
2026-08-20
Sell
1K
$824745
CASPER MARC N
director, officer: Chairman & CEO
2026-08-20
Sell
3K
$1.6M
CASPER MARC N
director, officer: Chairman & CEO
2026-08-21
Sell
3K
$1.9M
What you'll find
Next Thermo Fisher Scientific (TMO) earnings date, the expected move and the estimates priced in
A clear Beat / Miss / In-line / Mixed verdict the moment Thermo Fisher Scientific reports
Revenue & EPS versus estimates, guidance and segment trends
Multi-lens price forecast — analyst, quant, technical and options views
Deep research: red flags, risk decoder and earnings-call sentiment
Technicals, options / implied volatility and unusual-activity signals
Hedge-fund and legendary-investor 13F holdings in Thermo Fisher Scientific (TMO)
Side-by-side peer and historical earnings comparison
Frequently asked questions
When is Thermo Fisher Scientific's next earnings date?
Thermo Fisher Scientific's (TMO) next scheduled earnings date is Oct 28, 2026. Magnisto shows the confirmed date, the options-implied expected move and the revenue and EPS estimates Wall Street is modeling into the report.
Did Thermo Fisher Scientific (TMO) beat or miss earnings?
In Q2 FY2026, Thermo Fisher Scientific (TMO) posted beat results — revenue of $12.0B versus the $11.7B estimate (+2.5% surprise) and EPS of $6.03 versus $5.72 expected (+5.4% surprise). Magnisto decodes every Thermo Fisher Scientific (TMO) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
How often does Thermo Fisher Scientific beat earnings estimates?
Over its last 8 reported quarters, Thermo Fisher Scientific (TMO) beat Wall Street EPS estimates 5 times, most recently a beat result in Q3 FY2026. Magnisto tracks every Thermo Fisher Scientific (TMO) quarter's revenue and EPS versus consensus and grades each one Beat, Miss, In-line or Mixed at a unified ±2% threshold.
How much does Thermo Fisher Scientific stock move after earnings?
Over its last 8 quarterly reports, Thermo Fisher Scientific (TMO) moved an average of ±5.9% the day after earnings — ranging from -8.6% (Q2 FY2026) to +11.1% (Q3 FY2025). The stock rose after 4 of those 8 reports and fell after 4. Heading into its next report on Oct 28, 2026, options-implied volatility is pricing in a move of roughly ±10.5% (derived). Magnisto tracks the realized post-earnings move for every Thermo Fisher Scientific (TMO) quarter alongside the beat/miss verdict — past moves don't predict the next one.
Who are the largest shareholders of Thermo Fisher Scientific?
Institutions hold about 95.0% of Thermo Fisher Scientific's (TMO) shares outstanding as of the 2026-06-30 13F quarter. Its largest institutional holders include Blackrock, INC. (8.3%), Vanguard Capital Management LLC (6.5%), State Street Corp (4.5%). Magnisto lists Thermo Fisher Scientific's (TMO) top 13F holders with each stake size and its quarter-over-quarter change.
Are insiders buying or selling Thermo Fisher Scientific (TMO)?
In the most recent Form 4 filings Magnisto tracks, Thermo Fisher Scientific (TMO) insiders recorded 1 purchase and 11 sales — net selling. Insider transactions are one signal among many and are often routine (option exercises or scheduled 10b5-1 sales), so Magnisto shows the raw feed for you to judge.
What is the forecast for Thermo Fisher Scientific (TMO) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for Thermo Fisher Scientific (TMO), anchored to the current $628.74 share price, so you can weigh the bull, base and bear cases for Thermo Fisher Scientific side by side.
Is Thermo Fisher Scientific (TMO) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether Thermo Fisher Scientific fits your own thesis and risk profile. This is research, not investment advice.